Diamond CBD Generates Over One Million in Sales in 15 days | CashCropToday
0 Shares 167 Views

Diamond CBD Generates Over One Million in Sales in 15 days

February 27, 2018
167 Views

PotNetwork Holding (OTC: POTN), and its subsidiary Diamond CBD, Inc., generated over a million dollars in sales in the first two weeks of February. This brings Diamond CBD’s total sales to $3.5M for the first six weeks of 2018.

Diamond CBD has launched 15 uniquely marketed product lines such as its full spectrum CBD vape oil, infused gummies and honey sticks, topical’s, pet products, oils, and edibles. The growth from 2017 has been substantial. PotNetwork Holdings subsidiary has grown over 300% since this time last year.

Diamond CBD has recently partnered with Meds BioTech to develop a new product line aimed at targeting the personal wellness industry by offering CBD based dietary supplements.

To Buy Diamond CBD Product Click Here.

You may be interested

Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio Oregon
Market Watch
270 views
Market Watch
270 views

Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio Oregon

Editor - November 27, 2018

Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…

Wayland Group Enters UK Cannabis Market with Theros Pharma Acquisition
Global
194 views
Global
194 views

Wayland Group Enters UK Cannabis Market with Theros Pharma Acquisition

Editor - November 26, 2018

Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd. The Wayland Group…

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials
Manufacturing
190 views
Manufacturing
190 views

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials

Editor - November 26, 2018

GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…

Leave a Comment

Your email address will not be published.

Most from this category

%d bloggers like this: